Guidelines
UK Guidelines for the Management of Bone Sarcomas
Table 1
2002 WHO classification of malignant bone tumours [
16].
| Osteogenic tumours | Osteosarcoma | 9180/3 | Conventional | 9180/3 | Chondroblastic | 9181/3 | Fibroblastic | 9182/3 | Osteoblastic | 9180/3 | Telangiectatic | 9183/3 | Small cell | 9185/3 | Low-grade central | 9187/3 | Secondary | 9180/3 | | Parosteal | 9192/3 | | Periosteal | 9193/3 | | High grade surface | 9194/3 |
| Ewing sarcoma/primitive neuroectodermal tumour | Ewing sarcoma | 9260/3 |
| Cartilage | Chondrosarcoma | 9220/3 | Central, primary, and secondary | 9220/3 | Peripheral | 9221/3 | Differentiated | 9243/3 | Mesenchymal | 9240/3 | Clear cell | 9242/3 |
| Fibrogenic tumours | Fibrosarcoma | 8810/3 | Fibrohistiocytic tumours | | | Haemopoietic tumours | Plasma cell myeloma | 9732/3 | Malignant lymphoma, NOS | 9590/3 | Giant cell tumour | Malignancy in giant cell tumour | 9250/3 | Notochordal tumours | Chordoma | 9370/3 | Vascular tumours | Angiosarcoma | 9120/3 | Smooth muscle tumours | Leiomyosarcoma | 8890/3 | Lipogenic tumours | Liposarcoma | 8850/3 | Miscellaneous tumours | Adamantinoma | 9261/3 |
|
|